NCT06188624 Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
| NCT ID | NCT06188624 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
| Condition | Advanced Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 150 participants in total. It began in 2024-02-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers
Eligibility Criteria
Inclusion Criteria: * Subjects voluntarily join this study, sign the informed consent form, and have good compliance； * Age: 18-75 years; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months； * Histologically or cytologically diagnosed with advanced cancers; * Subjects with advanced malignancies who have failed standard therapy or lack effective treatment; * Major organs are functioning well; * Female and male subjects of childbearing potential should agree to practice contraception during the study and until 6 months after the completion of the study. Exclusion Criteria: * Current concomitant or ever presented with other malignancies within 2 years prior to the first dose; * Unresolved toxicity of Grade 1 or above according to CTCAE due to any prior anti-tumor therapy; * Significant surgical treatment, biopsy, or significant traumatic injury within 28 days prior to the first dose; * Long-term unhealed wounds or fractures * Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose; * A history of psychotropic drug abuse and cannot be abstained, or have a mental disorder; * Subjects with any severe and/or uncontrolled disease; * History of live attenuated vaccination within 2 weeks prior to the first dose or planned live attenuated vaccination during the study; * Previous history of unexplained severe allergies, hypersensitivity to monoclonal antibodies or exogenous human immunoglobulins, or hypersensitivity to TQB2922 for injection or its excipients; * According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patients or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06188624 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06188624 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06188624 currently recruiting?
Yes, NCT06188624 is actively recruiting participants. Contact the research team at zhangli@sysucc.org.cn for enrollment information.
Where is the NCT06188624 trial being conducted?
This trial is being conducted at Chongqing, China, Guangzhou, China, Guangzhou, China, Harbin, China and 11 additional locations.
Who is sponsoring the NCT06188624 clinical trial?
NCT06188624 is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.